ClinicalTrials.gg

HIV Infections clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 4,737 studies for HIV Infections across more than 10 countries. 247 are recruiting or about to start. 3,702 of them are mainly about HIV Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 7 narrower conditions too, such as Acquired Immunodeficiency Syndrome: 6,828 studies, 544 open.

ClinicalTrials.gov finds 10,190 studies for HIV Infections. How that becomes 4,736 here

This page counts the studies the registry files under HIV Infections, and those it files under no condition that list HIV Infectionsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 10,190Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −2,070Filed under a narrower condition, counted on its own pageAcquired Immunodeficiency Syndrome 1,898 · HIV Seropositivity 126 · AIDS Dementia Complex 16 · AIDS-related Kaposi sarcoma 10 · HIV-Associated Lipodystrophy Syndrome 9 · AIDS-Related Complex 7 · 1 more
  3. −18List HIV Infections as a condition, but the registry did not file them under itMost often written as “Chronic HIV Infection” (3), “Acute HIV Infection” (2), and “HIV Infection Primary” (2). The registry filed them under other conditions only, most often Hepatitis C, Chronic (2) and Hepatitis (2).
  4. −3,366Match it another way107 name it in the title, 7 in a keyword, and 3,252 by a synonym or other text the search reads.
  5. 4,736The count on this page56 of them list HIV Infections in their own words; the registry filed them under no condition.

Status

Completed
3,741
Status unknown
290
Terminated
232
Recruiting
159
Withdrawn
115
Active, not recruiting
93

Phase

Phase 1
1,006
Phase 2
934
Phase 3
608
Phase 4
414
Early Phase 1
10

Where

United States
2,803
Puerto Rico
331
South Africa
305
France
278
Spain
261
Canada
236

Who develops what

Add HIV Infections to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 23 programs from 6 companies, 22 with this as their studies’ main aim; 8 with a live phase 3 study; 3 primary completions in the next 12 months. Compare GlaxoSmithKline, Gilead Sciences and Merck here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Antiretroviral TherapyRecent, repeated
Evidence
  • NCT06214052 · GlaxoSmithKline · Phase 2 · background · “Antiretroviral therapy” · registered Jan 2024
  • NCT06039579 · GlaxoSmithKline · Phase 2 · background · “Antiretroviral therapy” · registered Aug 2023
  • NCT05330143 · Ascletis Pharma Inc. · Phase 2 · background · “Antiretroviral Therapy” · registered Mar 2022
  • NCT00461266 · Hoffmann-La Roche · Phase 4 · background · “Antiretroviral therapy” · registered Apr 2007
—23 studies

21 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
lenacapavirApproved: US 2022 · EU 2022☆ Track3 live phase-3 studies: NCT04994509, NCT04925752, NCT07682961Gilead Sciences
teropavimab☆ Track1 live phase-3 study: NCT07682961Gilead Sciences
zinlirvimab☆ Track1 live phase-3 study: NCT07682961Gilead Sciences
cabotegravirApproved: US 2021 · EU 2020☆ Track4 live phase-3 studies: NCT02951052, NCT06134362, NCT03299049GlaxoSmithKline
DolutegravirApproved: US 2013 · EU 2014☆ Track2 live phase-3 studies: NCT07393659, NCT05979311GlaxoSmithKline

The 5 in phase 3 with the nearest primary completion, of 23 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 12 Feb 2027 est.JL18008 · Jecho Biopharmaceuticals Co., Ltd. · Phase 2 main aimNCT07579741 A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders — primary endpoint: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) as Assessed by DAIDS v2.1 · 30 enrolled
  • 30 Jun 2027 est.Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried · Liaoning Chengda Biotechnology CO., LTD · Phase 4 named, not the main aimNCT07932132 Immunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human Immunodeficiency Virus (HIV) — primary endpoint: Seroconversion rate and geometric mean concentration (GMC) of rabies virus neutralizing antibodies at 14 days after completion of the full vaccination course · 160 enrolled
  • 28 Oct 2027 est.VH4524184 · GlaxoSmithKline · Phase 2 main aim+ VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets vs Lamivudinestudied with emtricitabine tenofovir alafenamideNCT07202546 A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) — primary endpoint: Percentage of Participants Achieving Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Suppression (<50 copies/millilitre) as per FDA Snapshot Methodology · 186 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in HIV Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Integrase inhibitors 16 open · Reverse transcriptase inhibitors 12 open · Tyrosine kinase inhibitors (TKIs) 2 open · Opioids 1 open · Antimitotic agents 1 open

Coming up

104studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger. 31 (19%) take children under 18. 14 (9%) are for women only and 14 (9%) for men only; 60 (38%) take healthy volunteers.

Recruiting studies that take each age, of 159
AgeWomenMen
106 (4%)6 (4%)
18127 (80%)131 (82%)
30125 (79%)125 (79%)
40125 (79%)123 (77%)
50127 (80%)127 (80%)
65113 (71%)114 (72%)
75110 (69%)109 (69%)
85106 (67%)105 (66%)

Across all 4,737 studies, recruiting or not: 36% stop at 75 or younger and 33% at 65; 27% take children; 8% are for women only and 6% for men only; 26% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long HIV Infections studies take

Of 165 phase 1 interventional studies under HIV Infections, half reached primary completion within 19 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 119 mo7–33 · 165 studies5 mo2–18 · 74 studies27 mo18–46 · 91 studies
Phase 1/247 mo22–73 · 42 studies—55 mo29–73 · 35 studies
Phase 231 mo17–58 · 98 studies19 mo12–31 · 34 studies38 mo22–74 · 64 studies
Phase 2/341 mo33–60 · 11 studies——
Phase 327 mo20–46 · 101 studies22 mo18–30 · 57 studies43 mo26–63 · 44 studies
Phase 435 mo23–44 · 91 studies—36 mo25–45 · 78 studies
Interventional, no phase28 mo16–45 · 402 studies—28 mo16–45 · 393 studies
Observational38 mo16–69 · 201 studies—37 mo16–69 · 187 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 4,737. Browse all 4,737 → or search them.